Ignite Creation Date:
2024-05-06 @ 6:18 PM
Last Modification Date:
2024-10-26 @ 2:45 PM
Study NCT ID:
NCT05614050
Status:
RECRUITING
Last Update Posted:
2023-07-07
First Post:
2022-11-06
Brief Title:
HsCRP in the Prognosis of Patients After PCIa Multi-center Study
Sponsor:
Wuhan Union Hospital China
Organization:
Wuhan Union Hospital China
Study Overview
Official Title:
High-sensitivity C-reactive Protein hsCRP in the Prognosis of Patients After Coronary Intervention PCI a Multi-center Prospective Study
Status:
RECRUITING
Status Verified Date:
2023-07
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
Coronary heart disease CAD is caused by myocardial ischemia hypoxia or necrosis due to coronary artery stenosis spasm or obstruction Although standard drug therapy can greatly improve the prognosis of patients with CAD after percutaneous coronary interventions PCI these patients are still at high risk of major adverse cardiovascular and cerebrovascular events MACCE At present the concept of residual inflammation risk RIR has aroused widespread concern RIR is an important independent risk in patients with CAD Previous studies indicated that hsCRP 2mg L was the definition standard of RIR in CAD in European and American people In China the impact of dynamic changes of hsCRP on MACCE in PCI population remains unclear Therefore in this study the investigators plan to recruit patients undergoing PCI and observe the impact of RIR by serial hsCRP measurements on the prognosis of these patients followed up for 1 years at 14 hospitals in China
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None